Related Patent Info

Provided is a method of producing nephron progenitor cells (NPC) and ureteric epithelial progenitor cells (UEPC) including a step of contacting intermediate mesoderm (IM) cells, differentiated from posterior primitive streak cells derived from hPSC, with FGF9 and/or FGF20 and/or FGF2 and optionally one or more selected from the group consisting of BMP7, heparin, a Wnt agonist and retinoic acid to thereby procude NPC and UEPC under conditions that induce aggregation of NPC and UEPC into renal organoids.

Provided is a method of differentiating human pluripotent stem cells (hPSCs) into neural crest stem cells (NCSCs) comprising steps of culturing hPSCs with at least two agents selected from the group consisting of a ROCK inhibitor, a GSK-3 inhibitor, an ALK receptor inhibitor and a BMP receptor inhibitor, wherein the differentiated NCSCs express at least one neural crest cell marker of differentiation selected from the group consisting of PAX3, P75, NGFR, SOX10, FOXD3, NESTIN, SNAI2, Ki67 and HNK-1, and at least one marker of pluripotency selected from the group consisting of NANOG, ZNF206, and OCT4.

Provided is a method for generating a population of podocytes comprising steps of contacting a population of pluripotent stem cells with a podocyte induction medium comprising (i) activin A, (ii) BMP, (iii) a GSK-3 inhibitor or a Wnt activator, (iv) VEGF, and (v) retinoic acid.

Provided is an episome for inducing transgene-free and germ line competent iPS cells comprising OCT4, KLF4, SOX2, cMYC, NANOG, LIN28, and NR5A2, especially wherein preferred embodiments may contain a polycistronic locus composed of at least two of said genes, and may further contain the microRNA 302/367 gene cluster, a positive selection marker like neomycin resistance, a negative selection marker like HSV-tk, or a combination thereof.

Provided is a method of producing mesenchymal stem cells from iPSCs comprising steps of; (1) iPSCs are cultured in the presence of a TGF-β inhibitor and in an atmosphere containing about 7 to 8 vol. % C02 for a period of time from about 20 day to about 35 days, (2) the cells obtained in (1) are transfered to a culture dish having a hydrophilic surface, and (3) the cells obtained in (2) are cultured in a medium containing a TGF-β inhibitor.

Provided is a culture medium capable of establishing expanded potential stem cell (EPSC) lines which resemble naive or ground state ES cells, but are also able to differentiate into placenta trophoblasts and the embryo proper, comprising steps of culturing a population of pluripotent cells in an expanded potential stem cell medium (EPSCM) containing one or more of a Ras-ERK inhibitor, a Src Kinase family (SFK) inhibitor, a GSK3 inhibitor, and a Wnt inhibitor,  wherein the EPSCM further comprises a Jun N-Terminal Kinase (JNK) inhibitor and/or a p38 inhibitor, LIF, or IGF-II.

Provided are a composition comprising a repressor of mitofusin gene expression, an inhibitor of mitofusin protein activity, or a mixture thereof as an active ingredient for promoting reprogramming a differentiated cell into a pluripotent stem cell, and a use thereof. The composition according to the present invention increases the efficiency of reprogramming as well as reduces the time required for reprogramming to produce pluripotent stem cells.

Provided is a method for making a vascularized human hollow organ comprising a step of engrafting a human intestinal organoid (HIO) obtained from a human iPS cell into an immune compromised organism wherein during said engrafting step said HIO forms mature intestinal tissue. Also provided is a method for further making a human intestinal tissue containing a functional enteric nervous system (ENS) comprising a step of contacting a vagal-like neural crest cells (NCC) derived from a human iPS cell with a three dimensional HIO and transplanting said HIO in vivo.

Provided are methods and compositions for generating or maintaining human iPS cells in culture including a use of a low osmolality medium comprising a base medium and supplements comprising a LIF polypeptide, a GSK3 inhibitor, and a MEK inhibitor; wherein the base medium has an osmolality of about 180 mOsm/kg to about 250 mOsm/kg.  In an embodiment, the human iPS cells cultured in the low osmolality medium express phenotypes, gene expression profiles, or markers characteristic to a naive state.

Provided is a method for improving at least one of DNA damage response, apoptosis response, genomic stability and glucose metabolism of an iPS cell derived from aged donors (A-iPSC) to levels approximating those from young donors (Y-iPSC) comprising a step of supplementing A-iPSC with at least one of (i) pluripotency factor ZSCANIO, (ii) GLUT3, and (iii) an exosome subunit, especially wherein excessive expression of GPX2 is inhibited by at least one of said supplementing.

Provided is a method for using one or more type 7 long terminal repeat (LTR7) nucleic acid sequences of type H human endogenous retroviruses (HERVH) for identifying primate naive pluripotent stem cells, wherein the LTR7/HERVH-associated transcription is used as a marker and the sequences comprise a binding motif for one or more of transcription factors selected from LBP9, Oct4, NANOG and /or Klf4.

Provided is a cell culture media composition for converting non-naive pluripotent stem cells into naive iPSCs which comprises a cocktail of compounds from each of the following groups: (1)cytokine, (2)GSK inhibitor, (3)ERK1/2 inhibitor, (4)JNK inhibitor, (5)bFGF, and (6)MAPK inhibitor in amounts effective to reprogram non-naive cells into TGFβ independent naive iPSCs.

Provided is a method for performing cellular reprogramming comprising steps of (a) contacting a somatic cell with an inhibitor of CAF-1 complex, Sumo2 or Nutd21, or combinations thereof, and (b)  subjecting the somatic cell to a reprogramming protocol. Such inhibitors can improve both the speed and efficiency of cellular reprogramming.

Provided is a method for obtaining Schwann cells by direct reprogramming comprising a step of introducing into somatic cells of a mammal, for example fibroblasts, vascular endothelial cells, or mesenchymal stem cells, at least one gene selected from the group consisting of SOX10 gene and KROX20 gene, or an expression product of said gene.

Provided is a method for culturing human pluripotent stem cells using a graphene substrate having a structure capable of allowing self-renewal and retaining pluripotency of human pluripotent stem cells without differentiation, thereby enabling a long-term culture while retaining pluripotency of the cells without co-culturing with feeder cells.

Provided is a method of resetting a human stem cell to a more naive state, the method comprising: (1) culturing a human stem cell to be reset in a first medium comprising a MEK inhibitor and preferably a STAT3 activator, and (2) sustaining the cell in a second medium comprising a MEK inhibitor and a PKC inhibitor, and preferably a GSK3 inhibitor and a STAT3 activator.

Provided is a method for correcting a dystrophin gene defect in a patient with Duchenne muscular dystrophy (DMD) through skipping of a mutant exon of the gene by means of CRISPR/Cas9-mediated gene editing, the method being applicable to a muscle cell, a satellite cell or an iPS cell from the DMDpatient.

Provided is a chemically defined media for the reprogramming of cells such as fibroblasts into cardiomyocytes, the media comprising a base tissue culture media, insulin-transferrin-selenium (ITS) or ascorbic acid, and the media may further comprising bovine serum albumin (BSA) or L-glutamine.

Disclosed is a method for inducing T cells for immunocytotherapy, comprising (1) a step of providing human pluripotent stem cells having a desired antigen-specific T cell receptor gene along with Rag1and/or Rag2 genes knocked out and (2) a step of inducing T cells from the pluripotent stem cells of step (1).

Provided is a method for preparing an iPS cell line from mesenchymal stem cells from a human umbilical cord with the use of a medium for dediferention containing an Ecklonia cava extract.

Provided is an efficient method for preparing iPS cells comprising reducing the amount and/or activity of one or more components of the CAF1 complex, and/or one or more components of the SUMO pathway in target cells.

Provided is a method for inducing T cells for immunotherapy, comprising steps of (1) providing human pluripotent stem cells having a WT1 antigen-specific T cell receptor or an EB virus antigen-specific T cell receptor; and (2) inducing progenitor T cells or mature T cells from the pluripotent stem cells of step (1).

Provided is a method for inducing T cells for immunotherapy, comprising steps of (1) providing pluripotent stem cells having a desired antigen-specific T cell receptor; and  (2) inducing T cells from the pluripotent stem cells of step (1).

Provided is a method for inducing T cells for immunotherapy, comprising steps of (1) providing pluripotent stem cells having a desired antigen-specific T cell receptor; and (2) inducing progenitor T cells or mature T cells from the pluripotent stem cells of step (1).

Provided are methods and compositions for inducing a somatic cell to acquire a less differentiated phenotype and for generating iPS cells by inducing expression of ASF1A in the cell and/or by contacting the cell with GDF9.

Provided is a method for generating an induced trophoblast stem cell (iTSC) from a cell, comprising a step of expressing in the cell at least one exogenous transcription factor selected from the group consisting of Gata3, Eomes and Tfap2c, with the proviso of not consisting of a step of expressing in the cell Eomes, Cdx2, Elf5, cMyc and Klf4.

This invention relates to a composition for inducing cell reprogramming; especially wherein an indazole derivative has been shown to improve the reprogramming efficiency greatly with no or little cytotoxicity.

Provided is a novel mutant hemagglutinin complex protein derived from Clostridium botulinum type B, in which at least subcomponents HA2 and HA3 of hemagglutinin are included and at least one amino acid of a glycosylation site is mutated, and with which it is possible to remove cells not remaining in undifferentiated state from a culture of pluripotent stem cells.

Provided are a novel synthetic peptide for inducing the reprogramming of differentiated cells, a pharmaceutical composition for inducing reprogramming including the same, and a method for producing undifferentiated cells from differentiated cells using the same.

Provided are novel 4-aminoquinoline derivatives, which are dual inhibitors of histone methyltransferases and DNA methyltransferases, pharmaceutical compositions containing the same, and their use in medicine, in particular as anticancer agents and as agents for generating induced pluripotent stem cells.